The earnings call reflected a mix of positive developments, such as revenue growth in key regions and pipeline advancements, alongside ongoing challenges, particularly in North America and Japan, and issues with the Indore facility. Despite these challenges, the overall outlook remains optimistic due to the strength of pipeline advancements and strategic initiatives.

Company Guidance

During the Viatris Second Quarter 2025 Earnings Conference Call, the company provided guidance emphasizing their strategic priorities and financial outlook for the year. Viatris achieved a 3% divestiture-adjusted operational revenue growth, excluding the impact from Indore, and highlighted advancements in their late-stage pipeline with positive results from 5 of 6 anticipated Phase III readouts. The Eye Care division is poised to become a significant contributor to the company, with promising data from ophthalmology programs. In terms of capital allocation, Viatris returned over $630 million to shareholders, including $350 million in share repurchases. The company reiterated its 2025 financial guidance, expecting to be in the top half of the range for revenue and adjusted EPS. Viatris is also focused on strategic business development opportunities and operational reviews to ensure sustainable growth beyond 2025.

Positive Revenue Growth

Viatris achieved 3% divestiture-adjusted operational revenue growth in Q2 2025, excluding the impact from Indore, driven by strength in Europe and Greater China.

Pipeline Advancements

Five of the six anticipated Phase III readouts showed positive results, including two ophthalmology programs targeting dim-like disturbances and presbyopia.

Shareholder Returns

Viatris returned more than $630 million to shareholders, including $350 million in share repurchases.

FDA Approvals and Progress

FDA approval for darunavir tablets manufactured at the Nashik facility was received, indicating progress in operational priorities.

Strong China Market Performance

Net sales in Greater China exceeded expectations and grew by 9%, driven by proactive patient choice and timing of customer purchasing patterns.

Viatris (VTRS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VTRS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	0.62 / -	0.75	―	―	―
Aug 07, 2025	2025 (Q2)	0.56 / 0.62	0.69	-10.14% (-0.07)
May 08, 2025	2025 (Q1)	0.49 / 0.50	0.67	-25.37% (-0.17)
Feb 27, 2025	2024 (Q4)	0.57 / 0.54	0.62	-12.90% (-0.08)
Nov 07, 2024	2024 (Q3)	0.68 / 0.75	0.789	-4.94% (-0.04)
Aug 08, 2024	2024 (Q2)	0.68 / 0.69	0.752	-8.24% (-0.06)
May 09, 2024	2024 (Q1)	0.67 / 0.67	0.774	-13.44% (-0.10)
Feb 28, 2024	2023 (Q4)	0.65 / 0.62	0.674	-8.01% (-0.05)
Nov 07, 2023	2023 (Q3)	0.75 / 0.79	0.873	-9.62% (-0.08)
Aug 07, 2023	2023 (Q2)	0.71 / 0.75	0.875	-14.06% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VTRS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$8.65	$9.28	+7.28%
May 08, 2025	$8.38	$8.86	+5.73%
Feb 27, 2025	$10.82	$9.17	-15.25%
Nov 07, 2024	$11.08	$12.57	+13.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.